Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibandronic acid - Roche

Next Previous
X
Search
Drug Profile

Ibandronic acid - Roche

Alternative Names: BM 210955; Bondronat; Boniva; Bonviva; CT-064; Ibandronate; Ibandronate sodium hydrate; Methylpentylaminopropylidene; R 484; RG484; RO 2005450; Ro200-5450; Ro200-5450iv; Ro200-5450po; RPR 102289A

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche; Taisho Pharmaceutical
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Cancer pain

Most Recent Events

  • 24 Nov 2022 Taisho Pharmaceutical acquires Ibandronic acid (Bonviva®) from Roche and Chugai Pharmaceutical
  • 06 Sep 2022 No development reported - Phase-III for Postmenopausal osteoporosis (In the elderly, In adults) in Denmark, Spain, Italy, Germany, Czech Republic, Hungary, United Kingdom (IV) (NDR Batch 23)
  • 31 Jul 2020 Roche completes a phase-III clinical trials in Postmenopausal osteoporosis (In adults, In the elderly) in Denmark, Italy, Germany, Czech Republic, Hungary and United Kingdom (IV) (EudraCT2004-002570-32) (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top